Scynexis Inc (SCYX) Stock Price & Analysis
Scynexis Inc (SCYX) fell 2.62% to USD 4.36 as of June 10, 2026 at 10:07 UTC, according to Nexqual real-time market data.
SCYX last closed at USD 4.48; the session ranged USD 4.28–4.75 on volume of 55,198 shares. Market capitalization is $43.30M, with a 52-week range of USD 4.28–10.48 (NCM). Source: Nexqual, June 10, 2026 at 10:07 UTC.
Key Statistics (as of June 10, 2026 at 10:07 UTC)
| Price | USD 4.36 |
|---|---|
| Change | ▼ 2.62% (down) |
| Previous Close | USD 4.48 |
| Open | USD 4.75 |
| Day Range | USD 4.28 – 4.75 |
| 52-Week Range | USD 4.28 – 10.48 |
| Volume | 55,198 shares |
| Market Cap | $43.30M |
| Exchange | NCM |
Technical Analysis (SCYX)
Nexqual's technical model rates SCYX "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 10:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 26.39 (oversold) |
| vs SMA50 | Below (USD 6.9) |
| MACD | -0.64 (negative) |
Analyst Ratings (SCYX)
Wall Street analysts rate SCYX "None" based on 3 analysts, with a mean price target of USD 33.55 (range USD 24–44.64), per Nexqual as of June 10, 2026 at 10:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 33.55 |
| High Target | USD 44.64 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (SCYX)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -0.51 |
| Revenue Estimate | $80,330 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.36 vs est -0.99 ▼ miss |
| 2025-12-31 | USD 2 vs est 1.01 ▲ beat |
| 2025-09-30 | USD -1.36 vs est -1.6 ▲ beat |
| 2025-06-30 | USD -1.12 vs est -1.52 ▲ beat |
Source: Nexqual, June 10, 2026 at 10:07 UTC.
Financials & Fundamentals (SCYX)
| Total Revenue | $20.34M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -119.95% |
| Profit Margin | -120.51% |
| ROE | -53.39% |
| Debt / Equity | 4.99 |
| Current Ratio | 3.94 |
| Total Cash | $59.26M |
| Total Debt | $2.06M |
| Free Cash Flow | $2.65M |
Source: Nexqual, June 10, 2026 at 10:07 UTC.
Financial Health Score (SCYX)
Nexqual rates Scynexis Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 10:07 UTC.
| Growth | Strong — Revenue +450% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $59M cash vs $2M debt, net cash position |
| Cash Flow | Solid — FCF $3M, 13% margin |
| Efficiency | Critical — ROE -53%, ROA -21.0% |
Ownership (SCYX)
| Insider Ownership | +2.10% |
|---|---|
| Institutional Ownership | +42.33% |
| Shares Outstanding | 9.93M |
| Float | 7.70M |
| Short % of Float | +3.31% |
Source: Nexqual, June 10, 2026 at 10:07 UTC.
Leadership (SCYX)
Scynexis Inc is led by David Gonzalez Angulo (age 60), CEO, President & Director, per Nexqual as of June 10, 2026 at 10:07 UTC.
| CEO, President & Director | David Gonzalez Angulo (age 60) |
|---|---|
| Chief Financial Officer | Ivor Macleod (age 64) |
| Vice President of Human Resources & Information Technology | Daniella Gigante |
Major Backers & Investors (SCYX)
Notable institutional backers of Scynexis Inc include Squadron Capital Management LLC, Great Point Partners LLC, Heights Capital Management, Inc , according to Nexqual as of June 10, 2026 at 10:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Squadron Capital Management LLC | 1.2% |
| Great Point Partners LLC | 1.19% |
| Heights Capital Management, Inc | 0.33% |
| Avidity Partners Management, LP | 0.33% |
| Kingdon Capital Management LLC | 0.31% |
| Empery Asset Management, LP | 0.29% |
| DAFNA Capital Management, LLC | 0.17% |
| Acadian Asset Management. LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.5% |
Source: Nexqual, June 10, 2026 at 10:07 UTC.
From Scynexis Inc's Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- We are developing our proprietary antifungal platform "fungerps", a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.
- A second generation fungerp SCY-247 is currently being evaluated in clinical trials and additional compounds from our proprietary fungerp platform, targeted to address significant unmet needs, are in earlier stages of development.
- Intellectual Property We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining patents intended to cover our product candidates and compositions, and their methods of use and other inventions that are commercially important to the development of our business.
Partnerships
- GSK has reiterated its commitment to continued collaboration with us regarding other aspects of the GSK License Agreement, including with respect to the commercialization of BREXAFEMME for VVC and rVVC indications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LPCN | Lipocine Inc. | USD 2.05 | ▲ 0% |
| CLSDQ | Clearside Biomedical, Inc. | USD 0.31 | ▲ 0% |
| CLRB | Cellectar Biosciences, Inc. | USD 2.36 | ▼ 8.88% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| FBIO | Fortress Biotech, Inc. | USD 2.93 | ▲ 10.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:07 UTC. This page is informational and not investment advice.